Welcome to our dedicated page for Akoya Biosciences news (Ticker: AKYA), a resource for investors and traders seeking the latest updates and insights on Akoya Biosciences stock.
This page contains historical news coverage for Akoya Biosciences Inc (AKYA), which operated as a life sciences technology company specializing in spatial biology platforms for tissue analysis. The company developed the CODEX system for high-parameter proteomic profiling in research applications. Akoya Biosciences received a delisting notification and is no longer traded on major U.S. stock exchanges.
The news archive documents the company's partnerships with pharmaceutical firms and research institutions, product development announcements, and financial performance during its period as a publicly traded entity. Historical coverage includes collaborations with organizations like Enable Medicine, Singapore Translational Cancer Consortium, and NeraCare, as well as the company's expansion of its biopharma services portfolio and spatial proteomics platform developments.
This archive provides context on Akoya's business trajectory, strategic initiatives in the spatial biology market, and the evolution of its technology platform before its delisting. Investors and researchers can review this historical record to understand the company's role in advancing tissue analysis methodologies and its position within the life sciences tools sector.
Akoya Biosciences (Nasdaq: AKYA) announced its participation in the 35th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) scheduled for November 10-14, 2021, in Washington, DC. The company will showcase data on its CODEX® and Phenoptics™ platforms, emphasizing their role in developing spatial phenotypic signatures for immuno-oncology biomarkers. A symposium on November 11 will discuss innovations in spatial biomarkers, featuring experts from various organizations. Attendees can also experience hands-on demonstrations at Akoya's booth.
Akoya Biosciences (Nasdaq: AKYA) announced its participation in two upcoming virtual investor conferences. The first is the Canaccord Genuity Virtual MedTech, Diagnostics, and Digital Health & Services Forum on November 18, where CEO Brian McKelligon will speak on the future of spatial biology at 1:00 p.m. ET. The second is the Piper Sandler 33rd Annual Virtual Healthcare Conference from November 30 to December 2, featuring a fireside chat with McKelligon and CFO Joe Driscoll, available starting November 22 at 10:00 a.m. ET.
Akoya Biosciences, recognized as The Spatial Biology Company®, announced the formation of the Akoya Imaging Innovators (I²) Network. This initiative aims to advance spatial biology by collaborating with leading researchers in various fields, including oncology and neuroscience, who will utilize Akoya's CODEX technology for single-cell spatial analysis. Members are selected for their innovative contributions, and the program provides access to CODEX systems and support from Akoya's experts, fostering transformative research in spatial phenotyping.
Akoya Biosciences (NASDAQ: AKYA) announced the appointment of Pascal Bamford, PhD, as Senior Vice President of Research and Development and Laboratory Operations, effective October 26, 2021. Dr. Bamford, with extensive experience in laboratory innovations, will drive the growth of Akoya’s spatial biology solutions and enhance the Advanced Biopharma Services (ABS) offerings. Previously, he held senior roles at Exact Sciences and Epic Sciences, contributing to significant product development in clinical diagnostics and oncology.
Akoya Biosciences (Nasdaq: AKYA) will release its Q3 2021 financial results on November 8, 2021, after market close. A conference call to discuss these results is scheduled for 5:00 p.m. ET, accessible via dial-in numbers for domestic and international callers. Akoya, known as The Spatial Biology Company®®, focuses on spatial phenotyping with solutions like CODEX® and Phenoptics™ to enhance research in biology and health by providing insights into cell organization and interactions.
Akoya Biosciences, Inc. (NASDAQ: AKYA) has appointed Dr. Myla Lai-Goldman to its board of directors. With extensive experience in the diagnostics industry, Dr. Lai-Goldman aims to enhance Akoya's efforts in spatial biology, which has potential applications in life sciences. CEO Brian McKelligon expressed excitement about her joining the team as the company enters a new growth phase. Dr. Lai-Goldman's background includes key roles at LabCorp and co-founding GeneCentric Therapeutics, positioning her to drive Akoya's mission of advancing patient care through innovative solutions.
Akoya Biosciences, known as The Spatial Biology Company®, announced its virtual participation in the Morgan Stanley 19th Annual Global Healthcare Conference. The event will feature a fireside chat with CEO Brian McKelligon and CFO Joe Driscoll on September 13, 2021, at 5:00 p.m. ET. A live webcast will be available on Akoya's website for 90 days following the event. Akoya specializes in spatial phenotyping and offers platforms like CODEX® and Phenoptics™ to enhance research in biology and human health.
Akoya Biosciences (Nasdaq: AKYA) reported strong financial results for Q2 2021, achieving total revenue of $13.1 million, a 53% increase from $8.6 million in Q2 2020. Notable growth in reagent sales reached $4.3 million, up from $1.5 million year-over-year. Gross profit was $8.1 million, with a gross profit margin of 62.2%. The company announced significant strategic initiatives, including a partnership with AstraZeneca and the launch of the Imaging Innovators Network, further solidifying its role in spatial biology.
Akoya Biosciences (Nasdaq: AKYA) will participate virtually in the Canaccord 41st Annual Growth Conference on August 11, 2021, at 2:00 p.m. ET. CEO Brian McKelligon is scheduled to present, providing insights into the company’s innovative spatial biology technologies that aid in understanding biology and health. Akoya specializes in single-cell imaging solutions, including the CODEX® and Phenoptics™ platforms, enhancing research in disease progression and treatment response. For inquiries, contact Canaccord sales representatives.
Akoya Biosciences, Inc. (Nasdaq: AKYA) will announce its financial results for Q2 2021 on August 10, 2021, after market close. The company will hold a conference call at 5:00 p.m. ET to discuss the results. Investors can join the call by dialing (833) 562-0146 for domestic or (661) 567-1226 for international participants, using Conference ID: 8057237. The webcast will also be available on Akoya's investor relations website.
Akoya specializes in spatial biology, offering solutions like CODEX® and Phenoptics™ to enhance cellular research.
FAQ
What is the current stock price of Akoya Biosciences (AKYA)?
What is the market cap of Akoya Biosciences (AKYA)?
